EQS-Adhoc

Achiko AG: Achiko concludes Phase 1 study of Project Gumnuts for Covid-19 testing - Seite 3

Achiko holds exclusive commercialisation rights to the technology underlying Project Gumnuts from Regenacellex.SL. It may be used to detect all types of Covid-19, but also many other pathogens. Achiko is looking forward to the completion of regulatory approval and getting the technology to market as quickly as possible, applying it in an array of test kits and other assay formats.

Headquartered in Zurich, we have offices in Hong Kong, Jakarta, Singapore and Seoul.
http://www.achiko.com

About Regenacellx.sl
We are a regenerative medicine company working with expert clinicians and scientists in the field of stem cells and small chemicals to advance cell replacement strategies to regenerate damaged tissues of the human body. In response to the global Covid-19 pandemic, we are developing next stage technology in the testing and diagnosis of pathogens as simple kits for home use or point of care (PoC) for a range of human diseases including Covid-19.
http://www.regenacellx.com/

Media contacts:

ACHIKO AG
Investor Relations
E: [e-mail]

Switzerland
Marcus Balogh
Farner Consulting Ltd.
E: [e-mail]
T: [phone]

Germany and Austria
Axel Mühlhaus / Dr Sönke Knop
edicto GmbH
E: [e-mail]
T: [phone]

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.